ACTRN12611001053910
Recruiting
Phase 1
A multi-centre, prospective, randomised pilot study of intravenous minocycline, 200mg 12 hourly for 5 doses, compared with standard care, in patients with ischaemic stroke treated with intravenous tissue plasminogen activator (tPA).A strategy to reduce haemorrhagic transformation
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Ischaemic stroke
- Sponsor
- Sir Charles Gairdner Hospital
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects must meet the standard inclusion criteria for use of intravenous tPA, be at least 18 years of age and provide informed consent.
Exclusion Criteria
- •Standard exclusion criteria for routine use of tPA
- •The critera for excluding use of tPA, as per the WA protocol for administration of intravenous tPA are;
- •1\. Uncertainty about time of stroke onset (eg. patients awakening from sleep)
- •2\. Coma or severe obtundation with fixed eye deviation and complete hemiplegia
- •3\. Hypertension: systolic blood pressure greater than or equal to 180mmHg; or diastolic blood pressure \>110mmHg on repeated measures prior to study.
- •4\. Clinical presentation suggestive of subarachnoid haemorrhage even if the CT scan is normal
- •5\. Presumed septic embolus
- •6\. Patient having received a heparin medication within the last 48 hours and has elevated APTT or has a known hereditary or acquired haemorrhagic diathesis (eg. INR or APTT greater than normal). Known lupus anticoagulant is not a contraindication to alteplase.
- •7\. INR \>1\.5 Known advanced liver disease, advanced right heart failure, or anticoagulation, and INR \> 1\.5 (no need to wait for INR result in the absence of the former three conditions)
- •8\. Known platelet count \<100,000 uL
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Mantra Multi Arm Surgical Robotic System - Clinical StudyCTRI/2020/11/029053Robosurg Med Tech Pvt Ltd SS Innovations Group Company12
Not yet recruiting
Not Applicable
The BETTER Surgery Pilot TrialPerioperative outcomesPACTR201609001780323Clinical Research Center50
Recruiting
Not Applicable
Australasian Follow-up Tracking and Enhancing Recovery after Acute Kidney Injury (AFTER-AKI)Acute kidney injuryRenal and Urogenital - Kidney diseaseACTRN12618002044202Austin Health200
Active, not recruiting
Not Applicable
A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis. - PURETHAL Grasses Rush studyAllergic (IgE-mediated) rhinitis/rhinoconjunctivitis due to sensitization to grass pollenMedDRA version: 12.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisMedDRA version: 12.0Level: LLTClassification code 10001726Term: Allergic rhinitis due to pollenMedDRA version: 12.0Level: LLTClassification code 10053741Term: Allergenic desensitization procedureEUCTR2009-015012-18-DEHAL Allergy BV
Active, not recruiting
Not Applicable
PURETHAL Birch Rush study.PURETHAL is indicated for specific immunotherapy (desensitisation) of IgE-mediated, inhaled allergy with symptoms of allergic rhinitis, allergic conjunctivitis and allergic bronchial asthma with an allergic background.MedDRA version: 16.0Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]EUCTR2013-000086-36-PLHAL Allergy B.V.120